Some have argued that epigenetic silencing of STING in tumor cells limits their potential as clinical therapeutics, yet the preclinical literature has focused on myeloid and dendritic cell activation as being the primary targets for therapeutic effect (15). The gene discussed is STING1; the disease is neoplasm.